Join Our Team

Careers

Join Our Team

The successful clinical translation of new technologies to the clinic requires a wide range of expertise. Our multi-disciplinary group of more than 100 prostate cancer scientists, physicians, trainees and healthcare employees from five leading Alberta health research institutions are working with an international collaborative network to achieve our translational research goals – to make a meaningful impact on health policy and the outcomes of patients living with prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by developing and successfully translating to the clinic innovative tests that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer.

Submit Your Resume

  • Accepted file types: pdf, doc, rtf.
    .pdf, .doc, .rtf

MLA Dr. Richard Starke Toured APCaRI Labs

The APCaRI laboratory in the Department of Oncology at the University of Alberta hosted an early morning visit on October 11 by Dr. Richard Starke, MLA for Vermilion-Lloydminster @RichardStarke. Dr. John Lewis led the tour of the facility and discussed the work being done by APCaRI members on using the in vivo chick embryo imaging technique to follow tumour motility through the vasculature, screening for metastasis-gene targets in human cancers to develop metastasis-blocking therapeutics, and the design of Nanostics’ prostate cancer diagnostic blood tests platform; ClarityDx Prostate. Later that day Richard Starke tweeted about his visit describing it as an incredible tour of @UAlberta research facilities!
Along with Dr.’s Starke and Lewis (from left to right in feature photo above) were technicians Mike Wong and Diana Pham, Nanostics COO Catalina Vasquez, technician Renjith Pillai and our Program manager Rume Djebah.

- Perrin Beatty